Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Allergan, Inc. et al v. Amneal Pharmaceuticals LLC et al
Case Number:
1:18-cv-01457
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
January 03, 2019
Allergan, St. Regis Drop 2 Short-Lived Restasis IP Suits
Allergan Inc. and the Saint Regis Mohawk Tribe on Thursday withdrew two patent infringement suits in Delaware federal court accusing Saptalis Pharmaceuticals LLC and Amneal Pharmaceuticals LLC of infringing a pair of patents covering the blockbuster dry-eye medication Restasis.
-
September 21, 2018
Allergan, Tribe Sue Pharma Co. Over Restasis Patent
Allergan PLC and the Saint Regis Mohawk Tribe slapped generic drug manufacturer Amneal Pharmaceuticals with a patent infringement suit over the dry-eye drug Restasis in Delaware federal court on Thursday, even as the fate of related patents for the drug hangs in the balance at the Federal Circuit.